In liquidation · Vrijwillige ontbinding – vereffening (CBE)

Aelin Therapeutics

BE0685688842

Rechtspersoon Public limited company 2 establishments

Aelin Therapeutics is filed with the CBE under the catch-all “Overige activiteiten van vrije beroepen en andere wetenschappelijke en technische activiteiten”. Also registered: healthcare practice, medical laboratory. Public Limited, started on 6 December 2017, 2 establishments.

Lieven Bauwensstraat 20, 8200 Brugge

Behind the company: Dave Pardo, Pieter Van Aerschot.

Start date

6 December 2017

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

  • Negative equity NBB

    More debt than assets in 4 of the last 4 fiscal years.

  • Tight liquidity NBB

    Cash and receivables cover 40 % of short-term debt in 2025; threshold 65 %.

  • Busy address KBO

    21 other companies have their registered office at the same address; threshold 10.

  • Legal situation KBO

    Vrijwillige ontbinding – vereffening according to the CBE.

Financials

Financial year 2025

Aelin Therapeutics from Brugge, company number BE0685688842, closed financial year 2025 with a result of € 313,335 after tax. For that financial year Aelin Therapeutics recorded revenue of € 30,000 and equity of € -3.2 million. Compared with financial year 2024, the result moved from € 41,100 to € 313,335. Profitable, and profit is growing. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on August 10, 2026.

What it is worth Caution

€ -3.2 million

▲ € 313,335 vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 313,335

▲ € 272,234 vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 1.8 million

▲ 15% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € -29.1 million.

Debts at end 2025

Bank debt

€ 5 million

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 208,959

▼ 13% vs 2024

Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 2904 days on average.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
2023202320242025Change 2024 → 2025
Revenue € 3,669 € 234 - € 30,000
Profit after taxes € -6,695,833 € 411,634 € 41,100 € 313,335 ▲ € 272,234
Equity € -3,989,795 € -3,578,162 € -3,537,061 € -3,223,727 ▲ € 313,335
Total debts € 6,321,340 € 5,390,875 € 5,338,274 € 5,306,134 ▼ 1%
Cash € 2,556,688 € 1,291,411 € 1,573,038 € 1,802,611 ▲ 15%
Retained profit € -29,823,125 € -29,411,492 € -29,370,391 € -29,057,057 ▲ € 313,335
Bank debt € 5,128,194 € 5,000,000 € 5,000,000 € 5,000,000
Balance sheet total € 3,718,041 € 1,908,890 € 1,829,513 € 2,098,207 ▲ 15%
Employees (FTE) 28.3 1 - -

Key figures of Aelin Therapeutics, fiscal years 2023 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Aelin Therapeutics?

What happened at Aelin Therapeutics in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aelin Therapeutics is active according to the CBE. Legal situation: Vrijwillige ontbinding – vereffening.

  • New annual accounts for financial year 2025: profit of € 313,335 (▲ € 272,234 vs 2024). filed late Source: NBB ↗
  • Dave Pardo became a director. NBB
  • Pieter Van Aerschot became a director. NBB
  • New establishment in Gent. KBO
  • New establishment in Leuven. KBO
  • Start of the company according to the CBE. KBO

In short

From € 6.7 million loss in 2023 to € 313,335 profit in 2025.

Paid € 942,627 in corporate taxes since 2023.

Best year ever: 2023, with € 411,634 profit.

Management

LSP V Coöperatieve LLA 30.9%
Fund+ NV 19.9%
BFV NV 16%
+3
Aelin Therapeutics

Behind Aelin Therapeutics are Dave Pardo and Pieter Van Aerschot. The shares are held by LSP V Coöperatieve LLA (30.9%), Fund+ NV (19.9%), Boehringer Ingelheim Venture Fund GmbH (16.9%), BFV NV (16%), Vlaams Interuniversitair Instituut voor Biotechnologie VZW (12%) and PMV NV (4%).

See the full network in the app

Directors

According to the 2025 annual accounts

Dave Pardo

Liquidator

Also active at: VANDERMAESEN VISWAREN, 'T GRAVENSTEEN, VIDTS RECYCLING

since 2023

Pieter Van Aerschot

Liquidator

Also active at: FLIN

since 2023

Shareholders

LSP V Coöperatieve LLA

30.9%

Fund+ NV

19.9%

BFV NV

16%

Novartis Bioventures Ltd

0.3%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Lieven Bauwensstraat 20

8200 Brugge

2.271.467.311

Gaston Geenslaan 1

3001 Leuven

Active since 6 December 2017

2.319.016.513

Technologiepark-Zwijnaarde 73A

9052 Gent

Active since 15 January 2021

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number
0685.688.842
VAT number
BE 0685.688.842
Registered office
Lieven Bauwensstraat 20, 8200 Brugge
Names & denominations
Aelin Therapeutics
Enterprise type
Rechtspersoon
Legal form
Public limited company
Legal situation
Vrijwillige ontbinding – vereffening
Start date
6 December 2017
Peppol
Active · Active since 5 Nov 2025
Activities · NACE

Overige activiteiten van vrije beroepen en andere wetenschappelijke en technische activiteiten, neg

Overige gespecialiseerde wetenschappelijke en technische activiteiten

Activiteiten van medische beeldvorming en medische laboratoria

Activiteiten van medische laboratoria

Frequently asked questions

What does Aelin Therapeutics do?
Aelin Therapeutics is filed with the CBE under the catch-all “Overige activiteiten van vrije beroepen en andere wetenschappelijke en technische activiteiten”. Also registered: healthcare practice, medical laboratory. Public Limited, started on 6 December 2017, 2 establishments.
What is the address of Aelin Therapeutics?
The registered office of Aelin Therapeutics is located at Lieven Bauwensstraat 20, 8200 Brugge.
Is Aelin Therapeutics still active?
Not as usual. The CBE lists Aelin Therapeutics with legal situation “Vrijwillige ontbinding – vereffening”.
Is Aelin Therapeutics registered on Peppol?
Yes, Aelin Therapeutics is registered on the Peppol network with ID 0208:0685688842.
What is the enterprise number of Aelin Therapeutics?
The enterprise number of Aelin Therapeutics is BE0685688842.
When was Aelin Therapeutics founded?
Aelin Therapeutics was founded on 6 December 2017.